DECEMBER 5-9, 2023

HENRY B. GONZALEZ CONVENTION CENTER

SAN ANTONIO, TEXAS

Media | Gallery | Contact

Home / 2023 SABCS^® / Preliminary Program

Preliminary Program

PRELIMINARY PROGRAM

Working titles/topics shown. Final titles and speakers will follow.
In person and virtual attendance is available.

Tuesday, December 5, 2023 All times are CENTRAL Time

12:00 pm - 1:55 pm

CONCURRENT SPECIAL SESSIONS

Special Session 1: New Drug Approvals for Metastatic Breast Cancer, Hemisfair Ballroom 1-2

Session Co-Moderator: Laleh Amiri-Kordestani, U.S. Food and Drug Administration, Silver Spring, Maryland

Session Co-Moderator: Martine J. Piccart, Institut Jules Bordet, Brussels, Belgium

Elacestrant

Mirat Shah, US Food and Drug Administration, Silver Spring, Maryland

Trastuzumab deruxtecan

Preeti Narayan, US Food and Drug Administration, Silver Spring, Maryland

Late breaking (new drugs currently under review)

Christy Osgood, US Food and Drug Administration, Silver Spring, Maryland

Panel Discussion

Janice Cowden, Metastatic Breast Cancer Alliance, Bradenton, Florida

Virginia Kaklamani, UT Health San Antonio, San Antonio Texas

Vassiliki Karantza, Merk Research Laboratories, Rahway, New Jersey

Flora Mulkey, US Food and Drug Administration, Silver Spring, Maryland

Additional panelist to be announced

Special Session 2: Prevention, Early Detection, and Interception, Stars at Night Ballroom 3-4

Moderator: Carol J. Fabian, University of Kansas Medical Center, Kansas City, Kansas

What is polygenic risk score and how is it used?

Suzette Delaloge, Gustave Roussy, Villejuif, France

Questions and Discussion

Hormone replacement and alternatives for women at population and moderately increased risk

Carol J. Fabian, University of Kansas Medical Center, Kansas City, Kansas

Cancer risk associated with exogenous hormone use in BRCA mutation

Joanne Kotsopoulos, Women's College Research Institute, Toronto, Ontario, Canada

Panel Discussion

Special Session 3: Social Determinants of Health— Impact on Cancer Care, Stars at Night Ballroom 1-2
Moderator: Amelie G. Ramirez, UT Health Science Center at San Antonio, San Antonio, Texas

What are social determinants of health and why are they important to cancer care?

Amelie G. Ramirez, UT Health Science Center San Antonio, San Antonio, Texas

Multilevel barriers to addressing social risks: Data from select NCI cancer settings

Brenda Adjei, National Cancer Institute, Bethesda, Maryland

How do hospitals/clinics utilize SDoH data?

Brian M. Rivers, Morehouse School of Medicine Cancer Health Equity Institute, Atlanta, Georgia

Once social determinants of health are determined, what processes need to be in place to reduce the burden on patients?

Sandi L. Pruitt, UT Southwestern Medical Center, Dallas, Texas

How is the impact of SDoH being evaluated at clinical/hospital and community levels?
Susan T. Vadaparampil, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida

Advocate response
Barbara Segarra, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico

Panel Discussion

1:55 pm - 2:05 pm	BREAK
2:05 pm - 3:05 pm	CONCURRENT WORKSHOPS
	Clinical Workshop: Tumor Agnostic Approaches to Care, Stars at Night Ballroom 1-2 Moderator: Sangeetha M. Reddy, UT Southwestern Medical Center, Dallas, Texas Agnostic trials in the field of targeted therapies Vivek Subbiah, UT MD Anderson Cancer Center, Houston, Texas ADC development across tumor types Joshua Z. Drago, Memorial Sloan Kettering Cancer Center, New York, New York Real-world data Mia A. Levy, Foundation Medicine, Inc., Cambridge, Massachusetts Defining a biologic entity that is sensitive to immunotherapeutic Marleen Kok, Netherlands Cancer Institute, Amsterdam, Netherlands Materials and Methods: Basic Science to Breast Oncology Workshop, Stars at Night Ballroom 3-4 Moderator: Neil Vasan, Columbia University Irving Medical Center, New York, New York Organoids Calvin J. Kuo, Stanford University, Stanford, California Single-cell sequencing Speaker to be announced Real-world genomics Pedram Razavi, Memorial Sloan Kettering Cancer Center, New York, New York Drug engineering and discovery John Irwin, University of California San Francisco, San Francisco, California
3:05 pm - 3:25 pm	BREAK
3:25 pm - 5:15 pm	CONCURRENT EDUCATIONAL SESSION BLOCK #1
	ED01: Latest Trends in Adjuvant Endocrine Therapy, Stars at Night Ballroom 3-4 Moderator: Fabrice André, Gustave Roussy, Villejuif, France Optimizing endocrine therapy in premenopausal women Vered Stearns, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland How to treat postmenopausal patients Rachel Freedman, Dana-Farber Cancer Institute, Boston, Massachusetts Who benefits from CDK 4/6 inhibitors and chemotherapy in the adjuvant setting? Otto Metzger, Dana-Farber Cancer Institute, Boston, Massachusetts ED02: Lobular Breast Cancer, Stars at Night Ballroom 1-2 Moderator: Steffi Oesterreich, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania Biological peculiarities of ILC Christine Desmedt, KU Leuven, Leuven, Belgium Diagnosis, prognosis, and surveillance: What is different? Tari A. King, Dana-Farber Cancer Institute, Boston, Massachusetts Innovative approaches for lobular breast cancer Jason Aboudi Mouabbi, UT MD Anderson Cancer Center, Houston, Texas Panelist: Siobhán Freeney, European Lobular Breast Cancer Foundation, Dublin, Ireland ED03: Overcoming Obesity-Associated Breast Cancer Risk, Hemisfair Ballroom 1-2 Moderator: Abenaa M. Brewster, UT MD Anderson Cancer Center, Houston, Texas How much weight loss is needed to break the obesity-cancer link? Stephen D. Hursting, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina Interventions: Medical and lifestyle Randy Seeley, University of Michigan, Ann Arbor, Michigan Impact of exercise on breast cancer outcomes Kerry S. Courneya, University of Alberta, Edmonton, Alberta, Canada Panelist: Joanne Taylor, Abcdiagnosis, London, England ED04: Treatment Post-CDK 4/6 Inhibitors, Hemisfair Ballroom 3 Moderator: Stephanie Graff, Lifespan Cancer Institute, Providence, Rhode Island Single agent endocrine therapy Carlos H. Barrios, Latin American Cooperative Oncology Group, Porto Alegre, Brazil Combination endocrine therapy Ruth O’Regan, University of Rochester, Rochester, New York When to transition to cytotoxics Erica Stringer-Reasor, University of Alabama at Birmingham, Birmingham, Alabama Panelist: Abigail Johnston, Surviving Breast Cancer, Orlando, Florida
5:15 pm - 5:30 pm	BREAK
5:30 pm - 6:30 pm	CONCURRENT POSTER SPOTLIGHT SESSIONS BLOCK #1 PS1 Less is More: Minimizing Surgical Treatment in Patients with Early Stage Breast Cancer, Stars at Night Ballroom 3-4 PS2 Improving QOL and Care delivery for the Breast Cancer Patient, Hemisfair Ballroom 1-2 PS3 Insights from Single Cell, Spatial, and Artificial Intelligence Approaches, Stars at Night Ballroom 1-2
Wednesday, December 6
7:00 am - 8:00 am	CONCURRENT POSTER SPOTLIGHT SESSIONS BLOCK #2 PS4 Gaps in the Timing, Treatment Selection, and Supportive Services for Cancer Care, Stars at Night Ballroom 3-4, PS5 Shining a New Light on Breast Cancer: Novel Molecular and Functional Imaging Approaches to Detect and Characterize Breast Cancer, Hemisfair Ballroom 1-2 PS6 Prognostic and Predictive uses of cell free DNA, Stars at Night Ballroom 1-2
8:00 am - 8:15 am	BREAK
8:15 am - 8:30 am	Welcome and Opening Remarks, Hall 1
8:30 am - 9:00 am	William L. McGuire Memorial Lecture, Hall 1 Jack Cuzick, Queen Mary University of London, London, England
9:00 am - 12:00 pm	GENERAL SESSION 1, Hall 1
12:00 pm	EXHIBITS OPEN, Halls 2-3
12:00 pm - 2:00 pm	POSTER SESSION 1, Halls 2-3
12:00 pm - 1:00 pm	Rapid Fire: Mini-Oral Presentations, Hemisfair Ballroom 1-2
1:00 pm - 2:00 pm	CONCURRENT SESSIONS
	Debate: Anthracyclines…To give or not to give? Stars at Night Ballroom 1-2 Moderator: Harold J. Burstein, Dana-Farber Cancer Institute, Boston, Massachusetts “For” Martine J. Piccart, Institut Jules Bordet, Brussels, Belgium “Against” Virginia F. Borges, University of Colorado Anshutz Medical Campus, Aurora, Colorado State-of-the-Art Session 1: Immunotherapy— Purpose, Resistance, and Toxicity, Stars at Night Ballroom 3-4 Moderator: Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Australia Biomarkers predicting immune related adverse events Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, Massachusetts Cellular therapies: What is the outlook for breast and other solid cancers? Valentina Hoyos Velez, Baylor College of Medicine, Houston, Texas Tumor mechanisms of resistance to immunotherapy Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Australia Chromosomal instability and resistance to immunotherapy Kevin Litchfield, University College London, London, England
2:00 pm - 3:00 pm	Molecular Tumor Board, Hemisfair Ballroom 1-2 Moderator: Pedram Razavi, Memorial Sloan Kettering Cancer Center, New York, New York Panelists: Giuseppe Curigliano, European Institute of Oncology, Milan, Italy Gaorav Gupta, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina Maryam Shirazi, Tempus Labs, Inc., Chicago, Illinois Nancy U. Lin, Dana-Farber Cancer Institute, Boston, Massachusetts Elizabeth A. Morris UC Davis School of Medicine, Sacramento, California Joyce A. O'Shaughnessy, Baylor University Medical Center, Dallas, Texas
3:00 pm - 3:10 pm	BREAK
3:10 pm - 5:00 pm	CONCURRENT EDUCATIONAL SESSION BLOCK #2
	ED05: Controversies in Local Regional Management, Hemisfair Ballroom 1-2 Moderator: Debra Patt, Texas Oncology, Austin, Texas Demystifying the axilla: Challenging scenarios in the upfront surgery setting and after neoadjuvant chemotherapy Andrea V. Barrio, Memorial Sloan Kettering Cancer Center, New York, New York When less is more: Patient-friendly radiation courses with WBI and PBI Icro Meattini, Università degli Studi di Firenze, Florence, Italy Surgical management of clinical stage I HER 2+ and triple negative breast cancer Anita Mamtani, Memorial Sloan Kettering Cancer Center, New York, New York Optimizing outcomes: Breast reconstruction technique and timing after mastectomy Marco Maricevich, Baylor College of Medicine, Houston, Texas Panelist: Jamie LaScala, Translational Center of Excellence in Breast Cancer, Penn Medicine, Philadelphia, Pennsylvania ED06: Coordinated Care of Brain Metastasis, Hemisfair Ballroom 3 Moderator: Carey K. Anders, Duke University Comprehensive Cancer Center, Durham, North Carolina Speakers: Rebecca Dent, National Cancer Centre Singapore, Singapore Christopher D. Lascola, Duke University Medical Center, Durham, North Carolina Nelson Moss, Memorial Sloan Kettering Cancer Center, New York, New York Helen A. Shih, Massachusetts General Hospital, Boston, Massachusetts Jeffrey Wefel, UT MD Anderson Cancer Center, Houston, Texas ED07: HER2+ Breast Cancer— Updates from the Clinic and the Lab, Stars at Night Ballroom 1-2 Moderator: Mothaffar F. Rimawi, Baylor College of Medicine, Houston, Texas Molecular determinates of response and resistance in HER2+ breast cancer Ron Bose, Washington University School of Medicine in St. Louis, St. Louis, Missouri Recent advances in systemic disease Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Australia Management of brain metastases Sarah L. Sammons, Dana-Farber Cancer Institute, Boston, Massachusetts Panelist: Terlisa Sheppard, Terlisa Fights Breast Cancer, Inc., Florida ED08: Toxicity Management— Next-Gen Therapies Means Next-Gen Toxicities, Stars at Night Ballroom 3-4 Moderator: Antonio C. Wolff, Johns Hopkins University, Baltimore, Maryland Antibody drug conjugates Heather L. McArthur, UT Southwestern Medical Center, Dallas, Texas Targeted therapeutics in hormone positive breast cancers Erica L. Mayer, Dana-Farber Cancer Institute, Boston, Massachusetts Immunotherapies: short and long term Douglas B. Johnson, Vanderbilt University Medical Center, Nashville, Tennessee Panelist: Sheila Johnson, Komen Advocates in Science, Swansea, Illinois
5:00 pm - 7:00 pm	POSTER SESSION 2, Halls 2-3
5:30 pm - 6:30 pm	CONCURRENT POSTER SPOTLIGHT SESSIONS BLOCK #3 PS7 Prevention, Stars at Night Ballroom 3-4 PS8 Antibody Drug Conjugates: Where are we headed? Hemisfair Ballroom 1-2 PS9 Exploiting Tumor Biology in HER2-positive Breast Cancer to Escalate or De-escalate Neoadjuvant Therapy, Stars at Night Ballroom 1-2
7:00 pm	EXHIBITS CLOSE, Halls 2-3
Thursday, December 7
7:00 am - 8:00 am	CONCURRENT POSTER SPOTLIGHT SESSIONS BLOCK #4 PS10 Refining Prediction of Cancer Risk and Outcomes, Stars at Night Ballroom 3-4 PS11 CNS Disease in Breast Cancer: Where are We Now and Can We do Better? Hemisfair Ballroom 1-2 PS12 Putting Brakes on the Cell Cycle: Understanding Mechanisms Governing CDK 4/6 inhibitor Resistance and Role for Novel Therapeutic Strategies, Stars at Night Ballroom 1-2
8:00 am - 8:15 am	BREAK
8:15 am - 11:15 am	General Session 2, Hall 1
11:20 am - 11:50 am	Plenary Lecture 1, Hall 1 Breast cancer evolution, immune evasion and metastasis driven by chromosomal instability Charles Swanton, The Francis Crick Institute, London, England
11:50 am - 12:00 pm	BREAK
12:00 pm	EXHIBITS OPEN, Halls 2-3
12:00 pm - 2:00 pm	POSTER SESSION 3, Halls 2-3
1:00 pm - 1:30 pm	AACR Distinguished Lectureship in Breast Cancer Research, supported by Aflac Inc., Stars at Night Ballroom 1-2
1:00 pm - 2:00 pm	CONCURRENT SESSIONS
	Clinical Case Discussions, Stars at Night Ballroom 3-4 Moderator: Matthew P. Goetz, Mayo Clinic College of Medicine and Science, Rochester, Minnesota Panelists: Fabrice André, Gustave Roussy, Villejuif, France Nadia Harbeck, LMU University Hospital, Munich, Germany Erica L. Mayer, Dana-Farber Cancer Institute, Boston, Massachusetts Aleix Prat, Hospital Clínic Barcelona, Barcelona, Spain Hope S. Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California State-of-the-Art Session 2: Implications of Senescence for Breast Cancer Biology and Treatment, Hemisfair Ballroom 1-2 Moderator: Justin M. Balko, Vanderbilt University, Nashville, Tennessee Cellular senescence: The Senescence-Associated Secretory Phenotype (SASP) and immunity Marcus Ruscetti, UMass Chan Medical School, Worcester, Massachusetts Implications of therapy induced senescence in breast cancer James G. Jackson, Tulane University School of Medicine, New Orleans, Louisiana Clinical trials and new therapeutics Shom Goel, Peter MacCallum Cancer Centre, Melbourne, Australia
2:00 pm - 3:00 pm	Clinical Controversies, Stars at Night Ballroom 3-4 Moderator: Lisa A. Carey, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina Are we ready to stop staging the axilla? Monica Morrow, Memorial Sloan Kettering Cancer Center, New York, New York Armando E. Giuliano, Cedars-Sinai Medical Center, Los Angeles, California How to treat small triple negative breast cancer Priyanka Sharma, University of Kansas Medical Center, Kansas City, Kansas Alexandra Thomas, Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina Biology or stage? Tailoring treatment for premenopausal women with nodal involvement, but low oncotype Eric P. Winer, Yale Cancer Center, New Haven, Connecticut Kevin M. Kalinsky, Emory Winship Cancer Institute, Atlanta, Georgia
3:00 pm - 3:10 pm	BREAK
3:10 pm - 5:00 pm	CONCURRENT EDUCATIONAL SESSION BLOCK #3
	ED09: Genomics for Clinical Research and Cancer Care, Stars at Night Ballroom 1-2 Moderator: Norah Lynn Henry, Rogel Cancer Center University of Michigan, Ann Arbor, Michigan Actionable mutations in breast cancer: Targeting the pathway Milan Radovich, Caris Life Sciences, Irving, Texas Tumor tissue vs. ctDNA Ben O'Leary, Royal Marsden Hospital, London, England When do you order and how to interpret genomic testing Jorge S. Reis-Filho, Memorial Sloan Kettering Cancer Center, New York, New York ED10: PI(3)king the Right Target, Stars at Night Ballroom 3-4 Moderator: Cynthia X. Ma, Washington University Siteman Cancer Center, Saint Louis, Missouri PI3 Kinase Neil Vasan, Columbia University Irving Medical Center, New York, New York AKT pathway Alex Toker, Beth Israel Deaconess Medical Center, Boston, Massachusetts mTOR pathway Robert J. Schneider, NYU Grossman School of Medicine, New York, New York ED11: Inflammatory Breast Cancer: Clinical Challenges, Evolving Concepts and Novel treatments (People’s Choice), Hemisfair Ballroom 1-2 Moderator: Filipa Lynce, Dana-Farber Cancer Institute, Boston, Massachusetts Is IBC a genomically different type of BC? Frederick Howard, University of Chicago, Chicago, Illinois Surgical controversies in IBC Antony Lucci, UT MD Anderson Cancer Center, Houston, Texas Approaches to radiation therapy in IBC Jennifer Bellon, Dana-Farber Cancer Institute, Boston, Massachusetts Panelists: Terry Arnold, The IBC Network Foundation, Sealy, Texas Ginny Mason, Inflammatory Breast Cancer Research Foundation, Broadway, Virginia
5:00 pm - 7:00 pm	POSTER SESSION 4, Halls 2-3
5:30 pm - 6:30 pm	CONCURRENT POSTER SPOTLIGHT SESSIONS BLOCK #5 PS13 Special Populations: Pregnancy, Male and Geriatric Patients, Stars at Night Ballroom 3-4 PS14 Setting Expectations for Toxicities Related to I/O Therapy, Hemisfair Ballroom 1-2 PS15 Novel Nuclear Receptor Targeting Therapies, Stars at Night Ballroom 1-2
7:00 pm	EXHIBITS CLOSE, Halls 2-3
Friday, December 8
7:00 am - 8:00 am	CONCURRENT POSTER SPOTLIGHT SESSIONS BLOCK #6 PS16 Enhancing Immunotherapy for Triple Negative Breast Cancer: Novel Therapies and Biomarkers, Stars at Night Ballroom 3-4 PS17: Biomarkers of Response and/or Resistance to Endocrine Based Therapies: Implications for Treatment Approaches, Hemisfair Ballroom 1-2 PS18 Disparate Care calls for Desperate Measures: Understanding Gaps in Quality of Care and Opportunities to Improve it, Stars at Night Ballroom 1-2
8:00 am - 8:15 am	BREAK
8:15 am - 11:15 am	General Session 3, Hall 1
11:15 am - 11:45 am	Plenary Lecture 2, Hall 1 Recent advances in triple negative breast cancer Melinda L. Telli, Stanford University School of Medicine, Stanford, California
11:45 am - 12:00 pm	BREAK
12:00 pm	EXHIBITS OPEN, Halls 2-3
12:00 pm - 2:00 pm	POSTER SESSION 5, Halls 2-3
1:00 pm - 1:30 pm	AACR Outstanding Investigator Award for Breast Cancer Research, supported by the Breast Cancer Research Foundation, Stars at Night Ballroom 1-2
1:30 pm - 2:30 pm	CONCURRENT SESSIONS
	Translational Research Controversies, Stars at Night Ballroom 3-4 Moderator: Komal Jhaveri, Memorial Sloan Kettering Cancer Center, New York, New York Baby-TAM Per Hall, Karolinska Institutet, Stockholm, Sweden Jack Cuzick, Queen Mary University of London, London, England When to do a window trial Mitchell Dowsett, Royal Marsden Hospital, London, England Sara A. Hurvitz, UCLA – University of California Los Angeles, Los Angeles, California Are we sequencing too late? Charles M. Perou, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina Fabrice André, Gustave Roussy, Villejuif, France State-of-the-Art Session 3: Targeting Mutant ER, Hemisfair Ballroom 1-2 Moderator: Aditya Bardia, Massachusetts General Hospital, Boston, Massachusetts Biological consequences of ESR1 mutation Geoffrey L. Greene, University of Chicago, Chicago, Illinois Tracking mutant ER using ctDNA François-Clément Bidard, Institut Curie, Paris, France The future of oral SERDs Erika P. Hamilton, Sarah Cannon Research Institute, Nashville, Tennessee
2:30 pm - 2:45 pm	BREAK
2:45 pm - 3:45 pm	Year in Review, Hall 1 Moderator: Carlos L. Arteaga, UT Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas Advanced Breast Cancer Mariana Chavez-Mac Gregor, UT MD Anderson, Houston, Texas Early Breast Cancer Ann H. Partridge, Dana-Farber Cancer Institute, Boston, Massachusetts Basic Science Heide L. Ford, University of Colorado Denver School of Medicine, Denver, Colorado Translational Jennifer K. Richer, University of Colorado Anshutz Medical Campus, Aurora, Colorado
3:45 pm - 4:00 pm	BREAK
4:00 pm	Exhibits Close, Hall 2-3
4:00 pm - 6:00 pm	View from the Trenches: What will You do on Monday Morning? Hall 1 Moderator: Sara M. Tolaney, Dana-Farber Cancer Institute, Boston, Massachusetts Panelists: Javier Cortes Castan, Ramón y Cajal University Hospital, Madrid, Spain Lesley Glenn, Project Life, Central Point, Oregon Sara A. Hurvitz, University of California Los Angeles, Los Angeles, California Joyce A. O'Shaughnessy, Baylor University Medical Center, Dallas, Texas Richard C. Zellars, Indiana University School of Medicine, Indianapolis, Indiana
Saturday, December 9
8:00 am - 12:00 pm	Career Development Forum
8:00 am - 8:45 am	Achieving Your Career Goals: Lessons from a Successful Scientist, Stars at Night Ballroom 1-2 Moderator: Kate Lathrop, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX Speaker to be announced
8:45 am - 9:00 am	BREAK
9:00 am - 11:00 am	Concurrent Workshops for Early Career Scientists (pre-registration required) Planning Your First Clinical Trial, Room 302 This workshop for residents, fellows, and early-stage clinical faculty will consist of a 60-minute panel discussion with expert clinical trialists followed by breakout into small groups for peer-to-peer evaluation of a clinical trial concept. Panelists: Carole Baas, Alamo Breast Cancer Foundation, Southlake, Texas Thomas Braun, University of Michigan, Ann Arbor, Michigan Dawn L. Hershman, Columbia University Medical Center, New York, New York Ruth O’Regan, University of Rochester, Rochester, New York Additional panelists to be announced Grant Writing Tips and Tricks, Room 303 This workshop for graduate students, fellows, and early-stage faculty will consist of a 60-minute panel discussion with expert grant writers and reviewers followed by breakout into small groups for peer-to-peer evaluation of a specific aims page. Panelists: David Gius, Mays Cancer Center at UT Health San Antonio, San Antonio, Texas Reuben S. Harris, UT Health San Antonio, San Antonio, Texas Additional panelists to be announced
9:00 am - 12:00 pm	Navigating Success: Women’s Career Development (pre-registration required), Room 304 Designed for women who have completed their traineeships, this workshop is a dynamic and inclusive event aimed to inspire and support women pursuing careers in scientific research. The workshop provides a platform for accomplished female scientists to share their experiences, offer mentorship, and discuss strategies to overcome gender-related challenges in the field. Through engaging talks, interactive sessions, and networking opportunities, participants gain valuable insights, build a strong support network, and acquire tools to thrive and excel in their scientific research careers. Setting the stage for success Anne Welsh, Psychologist and Executive Coach, Cambridge, Massachusetts Evidence-based strategies to address systemic barriers facing women researchers Reshma Jagsi, Emory University, Atlanta Georgia Title to be announced Amelie Ramirez, UT Health Sciences Center at San Antonio, San Antonio, Texas Additional Speakers to be announced Interactive Portion of Workshop Anne Welsh,Psychologist and Executive Coach, Cambridge, Massachusetts
11:00 am -12:00 pm	Networking and Career Roundtable Discussions (pre-registration required), Stars at Night Ballroom 1-2 The Networking and Career Roundtables provide interactive informational interviews with experts on a variety of topics that are important for career development. These discussions provide attendees with an opportunity to speak face-to-face with colleagues and potential collaborators. Early career investigators are encouraged to participate for the opportunity to meet respected senior investigators and connect with researchers of similar interests. Light refreshments will be provided. Topics and mentors to be announced.

DECEMBER 5-9, 2023

Home / 2023 SABCS® / Preliminary Program

Home / 2023 SABCS^® / Preliminary Program